MediaPharma Overview
- Year Founded
-
2009
- Status
-
Acquired/Merged
- Employees
-
1
- Latest Deal Type
-
M&A
MediaPharma General Information
Description
Developer of immuno-oncology drugs created for the treatment of cancer and other severe diseases with high medical needs. The company focuses on the research and development of humanized monoclonal antibodies, antibody-drug conjugates and therapeutic proteins for cancers that have become resistant to previous drug regimens, enabling physicians to provide effective treatment for cancer through oncology drugs.
Contact Information
Website
www.mediapharma.itCorporate Office
- Via Colonnetta, 50/A
- 66013 Chieti
- Italy
Corporate Office
- Via Colonnetta, 50/A
- 66013 Chieti
- Italy
MediaPharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 31-Dec-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC | Completed | Generating Revenue | ||||
| 2. Secondary Transaction - Private | 01-Mar-2021 | $451K | Completed | Generating Revenue | ||
| 1. Early Stage VC | 01-Oct-2012 | $451K | $451K | Completed | Generating Revenue |
MediaPharma Patents
MediaPharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3995829-A1 | Lgals3bp as a diagnostic, prognostic, and therapeutic biomarker in covid-19 and other cytokine storm conditions | Inactive | 09-Nov-2020 | ||
| WO-2022096732-A1 | Lgals3bp as a diagnostic, prognostic, and therapeutic biomarker in covid-19 and other cytokine storm conditions | Inactive | 09-Nov-2020 | ||
| EP-3880706-A1 | Bispecific antibodies directed against human 90k and either endosialin or her3 | Inactive | 12-Nov-2018 | ||
| WO-2020099235-A1 | Bispecific antibodies directed against human 90k and either endosialin or her3 | Inactive | 12-Nov-2018 | ||
| EP-3773739-A1 | Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer | Pending | 12-Apr-2018 | A61K47/6849 |
MediaPharma Signals
MediaPharma Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Filas | Venture Capital | Minority | ||
| Invent (Rome) | Venture Capital | Minority | ||
| Lazio Innova | Venture Capital | Minority | ||
| TOTO Costruzioni Generali | Corporation | Minority |
MediaPharma FAQs
-
When was MediaPharma founded?
MediaPharma was founded in 2009.
-
Where is MediaPharma headquartered?
MediaPharma is headquartered in Chieti, Italy.
-
What is the size of MediaPharma?
MediaPharma has 1 total employees.
-
What industry is MediaPharma in?
MediaPharma’s primary industry is Drug Discovery.
-
Is MediaPharma a private or public company?
MediaPharma is a Private company.
-
What is MediaPharma’s current revenue?
The current revenue for MediaPharma is .
-
How much funding has MediaPharma raised over time?
MediaPharma has raised $451K.
-
Who are MediaPharma’s investors?
Filas, Invent (Rome), Lazio Innova, and TOTO Costruzioni Generali have invested in MediaPharma.
-
When was MediaPharma acquired?
MediaPharma was acquired on 31-Dec-2021.
-
Who acquired MediaPharma?
MediaPharma was acquired by Fusion Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process